- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00786383
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
Phase 1 Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.
We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.
In order for a cancer to grow, it needs blood vessels to bring to it oxygen and food. Cancer cells can make growth factors that cause the abnormal growth of new blood vessels. This is called angiogenesis. Normally, new blood vessels do not grow in adults. Angiogenesis inhibitors are drugs that may prevent abnormal growth of blood vessels to tumors. IMC-1121B is an angiogenesis inhibitor. We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202-5112
- ImClone Investigational Site
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27710
- ImClone Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19111
- ImClone Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Patients with histopathologically-documented, measurable or evaluable (non-measurable), advanced primary or recurrent solid tumors who have not responded to standard therapy or for whom no standard therapy is available
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2 at study entry.
- Able to provide written informed consent.
- A life expectancy of >3 months.
Adequate hematologic function, as defined by:
- an absolute neutrophil count ≥1500/mm3
- a hemoglobin level ≥10 gm/dL
- a platelet count ≥100,000/mm3
Adequate hepatic function, as defined by:
- a total bilirubin level ≤1.5 x the upper limit of normal (ULN)
- aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 x the ULN or ≤5 x the ULN if known liver metastases
- Adequate renal function, as defined by a serum creatinine level ≤1.5 x the ULN.
- Use of effective contraception , if procreative potential exists.
- Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy
- Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.
Exclusion Criteria:
- Patients with large centrally-located pulmonary lesions adjacent to or invading large blood vessels.
- Patients who have had chemotherapy or therapeutic radiotherapy within 28 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or patients with ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
- Prior left chest wall radiotherapy or a cumulative anthracycline dose ≥300 mg/m2 (if the ejection fraction is within normal institutional limits, the patient can be enrolled).
- Any concurrent malignancy other than non-melanomatous skin cancer or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥3 years will be allowed to enter the trial.
Uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection requiring parenteral antibiotics
- symptomatic congestive heart failure (class III or IV of the New York Heart Association classification for heart disease)
- unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months
- uncontrolled hypertension (systolic blood pressure ≥160 mm Hg, diastolic blood pressure >100 mm Hg, found on two consecutive measurements separated by a 1-week period despite adequate medical support)
- clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia)
- uncontrolled diabetes
- psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
- patients with symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids; anticonvulsants are allowed)
- A serious or nonhealing active wound, ulcer, or bone fracture.
- Known human immunodeficiency-positivity.
- A major surgical procedure, an open biopsy, or a significant traumatic injury within 28 days prior to treatment.
- Current or recent use (within 28 days) of a thrombolytic agent.
- Current or recent use (within 28 days) of full-dose warfarin (an exception is low-dose warfarin to maintain patency of preexisting, permanent, indwelling intravenous (i.v.) catheters; for patients receiving warfarin, the international normalized ratio [INR] should be <1.5). Patients requiring heparin are excluded.
- Chronic daily treatment with aspirin (>325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function (cyclooxygenase-2 [COX-2] inhibitors are permitted).
- A history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) within the last 6 months prior to study entry.
- Proteinuria ≥1+ by routine urinalysis (patients with a protein value of ≤500 mg confirmed by a 24-hour urine collection are eligible).
- Pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG]) or breast feeding.
- Prior treatment with bevacizumab or other agents specifically targeting VEGF ligand or receptor within 6 weeks of study entry.
- Monoclonal antibodies within 6 weeks of study entry.
- Positive anti-IMC-1121B antibody response.
- A history of allergic reactions to monoclonal antibodies or other therapeutic proteins.
- The subject is the investigator, sub-investigator, or anyone directly involved in the conduct of the protocol.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: IMC-1121B
IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort.
When all patients complete a cohort, dose escalation to the next cohort will occur.
|
Cohort 1 6 mg/kg I.V., once every other week for 4 weeks Cohort 2 8mg/kg I.V., once every other week for 4 weeks Cohort 3 10 mg/kg I.V., once every other week for 4 weeks Cohort 4 15 mg/kg I.V., once every 3 weeks for 6 weeks Cohort 5 20 mg/kg I.V., once every 3 weeks for 6 weeks |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Number of participants with Adverse Events (AEs)
Časové okno: 8 Weeks
|
8 Weeks
|
Maximum Tolerated Dose
Časové okno: 8 Weeks
|
8 Weeks
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Maximum concentration (Cmax), cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Minimum concentration (Cmin), cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Area under concentration (AUC), cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Half-life (t 1/2), cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Clearance (Cl) rate drug is completely removed, cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Volume of distribution (Vss) at steady state, cohorts 1, 2, 3, 4, and 5
Časové okno: 8 Weeks
|
8 Weeks
|
Serum Anti-IMC-1121B Antibody Assessment (immunogenicity)
Časové okno: 8 Weeks
|
8 Weeks
|
Change in tumor size from Baseline Measurement
Časové okno: 8 Weeks
|
8 Weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 13919
- CP12-0402 (Jiný identifikátor: ImClone Systems)
- I4T-IE-JVBN (Jiný identifikátor: Eli Lilly and Company)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na IMC-1121B
-
Eli Lilly and CompanyDokončenoPokročilé pevné nádorySpojené státy
-
Eli Lilly and CompanyDokončenoHepatocelulární karcinomSpojené státy, Kanada, Belgie, Německo, Izrael, Korejská republika, Španělsko, Austrálie, Rakousko, Brazílie, Francie, Itálie, Japonsko, Portugalsko, Tchaj-wan, Rumunsko, Bulharsko, Česká republika, Finsko, Hongkong, Maďarsko, Holan... a více
-
Eli Lilly and CompanyDokončenoStudie IMC-1121B (Ramucirumab) u účastníků s rakovinou jater, kteří dosud nebyli léčeni chemoterapiíHepatocelulární karcinomSpojené státy
-
Eli Lilly and CompanyDokončenoRakovina prsuSpojené státy, Kanada, Austrálie, Belgie, Brazílie, Chorvatsko, Česko, Egypt, Německo, Irsko, Izrael, Korejská republika, Libanon, Nový Zéland, Peru, Polsko, Ruská Federace, Srbsko, Slovensko, Jižní Afrika, Španělsko, Tchaj-wan, Spojené...
-
Eli Lilly and CompanyJiž není k dispoziciMetastatický karcinom žaludku | Metastatický adenokarcinom gastroezofageální junkceNěmecko, Holandsko, Rakousko, Řecko, Korejská republika
-
Eli Lilly and CompanyDokončenoRakovina vaječníků | Rakovina vejcovodů | Primární peritoneální karcinomSpojené státy, Spojené království
-
Eli Lilly and CompanyDokončenoAdenokarcinom žaludku | Adenokarcinom gastroezofageální junkceSpojené státy, Polsko, Rumunsko, Maďarsko, Ruská Federace, Austrálie, Francie, Argentina, Spojené království, Nový Zéland, Krocan, Slovensko
-
Eli Lilly and CompanyChildren's Oncology GroupDokončenoRecidivující nádor | Pediatrický pevný nádor | Refrakterní nádor | Malignity CNSSpojené státy
-
Eli Lilly and CompanyDokončeno